Tumor Biology

, Volume 36, Issue 2, pp 1207–1212 | Cite as

Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer

  • Hye min Kim
  • Sang Kyum Kim
  • Woo Hee Jung
  • Ja Seung Koo
Research Article


The purpose of this study is to examine the expression of Yes-associated protein (YAP) in metaplastic carcinoma and compare to those of triple-negative breast carcinoma (TNBC) for investigation of its implication. Tissue microarrays containing 34 cases of metaplastic carcinoma and 175 cases of TNBC were constructed and immunohistochemical staining was used to evaluate expression of the following proteins: YAP and phosphorylated YAP (pYAP). According to immunohistochemical staining results of cytokeratin 5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, STAT-1, androgen receptor, and GGT-1, metaplastic carcinoma and TNBC were sub-classified into six subtypes: basal-like type, molecular apocrine type, claudin-low type, immune-related type, mixed type, and null type. Comparing the expression of YAP and pYAP in metaplastic carcinoma and TNBC, the expression of nuclear YAP (p = 0.025), cytoplasmic pYAP (p = 0.010), and nuclear pYAP (p = 0.014) in tumor cell was higher in metaplastic carcinoma than TNBC. In metaplastic carcinoma, the nuclear YAP expression in tumor cell was associated with loss of E-cadherin (p = 0.020) and claudin type (p = 0.020), and the stromal YAP expression was associated with claudin 7 positivity (p = 0.003). In conclusion, the YAP expression in metaplastic carcinoma is higher than that in TNBC, representing the association of stemness and epithelial-mesenchymal transition features in metaplastic carcinoma.


Breast cancer Metaplastic carcinoma YAP 



This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A1002886).

Conflicts of interest


Supplementary material

13277_2014_2735_MOESM1_ESM.doc (62 kb)
ESM 1 (DOC 62 kb)


  1. 1.
    Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13(8):877–83.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 2003;11(1):11–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Stalsberg H, Thomas DB. Age distribution of histologic types of breast carcinoma. Int J Cancer. 1993;54(1):1–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ. WHO classification of tumors of the breast. Geneva: WHO; 2012.Google Scholar
  6. 6.
    Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108–18.CrossRefPubMedGoogle Scholar
  7. 7.
    Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16 Suppl 1:61–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim GJ, Kim H, Park YN. Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 2013;8(9):e75449.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26(57):7859–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Choi J, Jung WH, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol. 2012;27(11):1481–93.PubMedGoogle Scholar
  13. 13.
    Vlug EJ, van de Ven RA, Vermeulen JF, Bult P, van Diest PJ, Derksen PW. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr). 2013;36(5):375–84.CrossRefGoogle Scholar
  14. 14.
    Tufail R, Jorda M, Zhao W, Reis I, Nawaz Z. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat. 2012;131(3):743–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Quan T, Xu Y, Qin Z, Robichaud P, Betcher S, Calderone K, et al. Elevated YAP and its downstream targets CCN1 and CCN2 in basal cell carcinoma: impact on keratinocyte proliferation and stromal cell activation. Am J Pathol. 2014. doi: 10.1016/j.ajpath.2013.12.017.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Reddy P, Deguchi M, Cheng Y, Hsueh AJ. Actin cytoskeleton regulates Hippo signaling. PLoS One. 2013;8(9):e73763.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo AF, et al. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast. 2012;21(3):354–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Carter MR, Hornick JL, Lester S, Fletcher CD. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30(3):300–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253–67.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394(3):623–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hye min Kim
    • 1
  • Sang Kyum Kim
    • 1
  • Woo Hee Jung
    • 1
  • Ja Seung Koo
    • 1
  1. 1.Department of PathologyYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations